Targeted BRAF/MEK Inhibitor Combination Achieves Long-Term Survival in Melanoma

Source: Targeted Oncology, June 2017

More than one-fourth of patients with advanced BRAF V600-mutant melanoma remained alive at 5 years after treatment with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), long-term follow-up from a randomized trial showed.1

In the subgroup of patients with normal baseline lactate dehydrogenase (LDH) and fewer than 3 organ sites with metastases, half remained at alive at 5 years. No new safety signals emerged during long-term follow-up, as reported at the 2017 ASCO Annual Meeting in Chicago.

“This is the longest follow-up for any randomized trial evaluating a BRAF inhibitor combined with a MEK inhibitor,” said Jeffrey Weber, MD, a medical oncologist at NYU-Langone Medical Center in New York, who presented the findings during the meeting. “Long-term survival is achievable with dabrafenib-trametinib in patients with BRAF V600-mutant metastatic melanoma, particularly those with favorable baseline factors. “

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories